[A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].

Abstract

Recently, many patients have been treated with aromatase inhibitors(AI), either in an adjuvant setting or as a treatment for recurrence. The efficacy and safety of high-dose toremifene(HD-TOR)were evaluated in 18 patients with advanced/recurrent breast cancer. Twelve of the 18 patients had received AI just prior to the study treatment. The clinical benefit rate was 56%(PR: 28%, long SD: 28%). Progression-free median survival was 5. 5 months. Adverse events were mild and toremifene was well-tolerated. The results suggest that HD-TOR should be considered early on as a second-line treatment, or as a later treatment option for AI-resistant breast cancer.

• Authors: Hideyuki Tokura, Masato Fujisaki, Takayuki Takahashi, Yutaka Takigawa, Shigeki Onouchi, Kaou Matsuda, Akira Hirata
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 7 Pg. 1071-3 (Jul 2012) ISSN: 0385-0684 [Print] Japan
• PMID: 22790041 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Toremifene

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis
• Recurrence
• Salvage Therapy
• Toremifene (administration & dosage, therapeutic use)